hydrocortisone

Hydrocortisone is the pharmaceutical term for cortisol used in oral administration, intravenous injection, or topical application. It is used as an immunosuppressive drug, given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients needing steroid treatment but unable to take oral medication, and perioperatively in patients on long-term steroid treatment to prevent an adrenal crisis. It may also be injected into inflamed joints resulting from diseases such as gout.{{cn|date=November 2024}}

It may be used topically for allergic rashes, eczema, psoriasis, itching, and other inflammatory skin conditions. Topical hydrocortisone creams and ointments are available in most countries without prescription in strengths ranging from 0.05% to 2.5% (depending on local regulations) with stronger forms available by prescription only.{{Citation needed|date=November 2023}}

It may also be used rectally in suppositories to relieve the swelling, itch, and irritation in hemorrhoids.

It may be used as an acetate form (hydrocortisone acetate), which has slightly different pharmacokinetics and pharmacodynamics.{{cite journal |vauthors=Leite FM, Longui CA, Kochi C, Faria CD, Borghi M, Calliari LE, Monte O |title=[Comparative study of prednisolone versus hydrocortisone acetate for treatment of patients with the classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency] |language=Portuguese |journal=Arq Bras Endocrinol Metabol |volume=52 |issue=1 |pages=101–8 |date=February 2008 |pmid=18345402 |doi=10.1590/s0004-27302008000100014|doi-access=free }}

File:Cortisol for injection.jpg|Cortisol for injection

File:Tube of hydrocortisone cream.jpg|A tube of hydrocortisone cream, purchased over-the-counter

File:Hydrocortisone Cortef 10 mg Кортеф Гидрокортизон.jpg|Hydrocortisone 10 mg oral tablets (depicted a package for Russian market)

Hydrocortisone is a corticosteroid, acting specifically as both a glucocorticoid and as a mineralocorticoid. That is, it is an agonist of the glucocorticoid and mineralocorticoid receptors.{{cn|date=November 2024}}

Hydrocortisone has low potency relative to synthetic corticosteroids.{{cite journal | vauthors = Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H | title = A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy | journal = Allergy Asthma Clin Immunol | volume = 9 | issue = 1 | pages = 30 | date = August 2013 | pmid = 23947590 | pmc = 3765115 | doi = 10.1186/1710-1492-9-30 | doi-access = free | url = }} Compared to hydrocortisone, prednisolone is about 4{{nbsp}}times as potent and dexamethasone about 40{{nbsp}}times as potent in terms of anti-inflammatory effect.{{cite web|title=Dexamethasone|url=https://www.drugs.com/pro/dexamethasone.html|publisher=drugs.com|access-date=14 June 2013|url-status=live|archive-url=https://web.archive.org/web/20130621041355/http://www.drugs.com/pro/dexamethasone.html|archive-date=21 June 2013}} Prednisolone can also be used as cortisol replacement, and at replacement dose levels (rather than anti-inflammatory levels), prednisolone is about 8{{nbsp}}times more potent than cortisol.{{cite journal | vauthors = Caldato MC, Fernandes VT, Kater CE | title = One-year clinical evaluation of single morning dose prednisolone therapy for 21-hydroxylase deficiency | journal = Arquivos Brasileiros de Endocrinologia e Metabologia | volume = 48 | issue = 5 | pages = 705–712 | date = October 2004 | pmid = 15761542 | doi = 10.1590/S0004-27302004000500017 | doi-access = free | s2cid = 13986916 }} The equivalent doses and relative potencies of hydrocortisone compared to various other synthetic corticosteroids have also been reviewed and summarized.

The endogenous production rate of cortisol is approximately 5.7 to 9.9{{nbsp}}mg/m² per day, which corresponds to an oral hydrocortisone dose of approximately 15 to 20{{nbsp}}mg/day (for a 70-kg person).{{cite book | vauthors=Arvat E, Falorni A | title=Cortisol Excess and Insufficiency | publisher=S. Karger AG | series=Frontiers of Hormone Research | year=2016 | isbn=978-3-318-05840-6 | url=https://books.google.com/books?id=jew6DAAAQBAJ&pg=RA1-PA61 | access-date=10 April 2023 | page=1-PA61 | archive-date=27 April 2023 | archive-url=https://web.archive.org/web/20230427010953/https://books.google.com/books?id=jew6DAAAQBAJ&pg=RA1-PA61 | url-status=live }}{{cite book | veditors = Ghizzoni L, Cappa M, Chrousos GP, Loche S, Maghnie M | date = 2011 | title = Pediatric Adrenal Diseases: Workshop, May 16-18, 2010, Turin (Italy) | publisher = Karger Medical and Scientific Publishers | pages = 174– | isbn = 978-3-8055-9643-5 | oclc = 1020003143 | url = https://books.google.com/books?id=gde44-zDr_oC&pg=PA174 | access-date = 10 April 2023 | archive-date = 10 April 2023 | archive-url = https://web.archive.org/web/20230410220229/https://books.google.com/books?id=gde44-zDr_oC&pg=PA174 | url-status = live }} One review described daily cortisol production of 10{{nbsp}}mg in healthy volunteers and reported that daily cortisol production could increase up to 400{{nbsp}}mg in conditions of severe stress (e.g., surgery).

The total and/or free concentrations of cortisol/hydrocortisone required for various glucocorticoid effects have been determined.

The bioavailability of oral hydrocortisone is about 96% ± 20% (SD). The pharmacokinetics of hydrocortisone are non-linear. The peak level of oral hydrocortisone is 15.3 ± 2.9 (SD) μg/L per 1{{nbsp}}mg dose. The time to peak concentrations of oral hydrocortisone is 1.2 ± 0.4 (SD) hours.

The topical percutaneous absorption of hydrocortisone varies widely depending on experimental circumstances and has been reported to range from 0.5 to 14.9% in different studies.{{cite journal | vauthors = Wester RC, Maibach HI | title = Percutaneous absorption of topical corticosteroids | journal = Current Problems in Dermatology | volume = 21 | issue = | pages = 45–60 | date = 1993 | pmid = 8299376 | doi = 10.1159/000422362 | isbn = 978-3-8055-5712-2 }} Some skin application sites, like the scrotum and vulva, absorb hydrocortisone much more efficiently than other application sites, like the forearm.{{cite journal | vauthors = Bormann JL, Maibach HI | title = Effects of anatomical location on in vivo percutaneous penetration in man | journal = Cutaneous and Ocular Toxicology | volume = 39 | issue = 3 | pages = 213–222 | date = September 2020 | pmid = 32643443 | doi = 10.1080/15569527.2020.1787434 | s2cid = 220439810 }}{{cite book | title = Percutaneous Absorption | vauthors = Wester RC, Maibach HI | chapter = Regional Variation in Percutaneous Absorption | date = 8 June 2021 | pages = 165–174 | publisher = CRC Press | doi = 10.1201/9780429202971-11 | isbn = 978-0-429-20297-1 | s2cid = 132864025 | url = }} In one study, the amount of hydrocortisone absorbed ranged from 0.2% to 36.2% depending on the application site, with the ball of the foot having the lowest absorption and the scrotum having the highest absorption. The absorption of hydrocortisone by the vulva has ranged from 4.4 to 8.1%, relative to 1.3 to 2.8% for the arm, in different studies and subjects.{{cite journal | vauthors = Britz MB, Maibach HI, Anjo DM | title = Human percutaneous penetration of hydrocortisone: the vulva | journal = Archives of Dermatological Research | volume = 267 | issue = 3 | pages = 313–316 | date = 1980 | pmid = 7406539 | doi = 10.1007/BF00403852 | s2cid = 33367289 }}{{cite journal | vauthors = Oriba HA, Bucks DA, Maibach HI | title = Percutaneous absorption of hydrocortisone and testosterone on the vulva and forearm: effect of the menopause and site | journal = The British Journal of Dermatology | volume = 134 | issue = 2 | pages = 229–233 | date = February 1996 | pmid = 8746334 | doi = 10.1111/j.1365-2133.1996.tb07606.x | s2cid = 30076779 }}

Most cortisol in the blood (all but about 4%) is bound to proteins, including corticosteroid binding globulin (CBG) and serum albumin. A pharmacokinetic review stated that 92% ± 2% (SD) (92–93%) of hydrocortisone is plasma protein-bound. Free cortisol passes easily through cellular membranes.{{cite journal | vauthors = Charmandari E, Johnston A, Brook CG, Hindmarsh PC | title = Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency | journal = The Journal of Endocrinology | volume = 169 | issue = 1 | pages = 65–70 | date = April 2001 | pmid = 11250647 | doi = 10.1677/joe.0.1690065 | doi-access = free }} Inside cells it interacts with corticosteroid receptors.{{cite book |vauthors=Boron WF, Boulpaep EL | title = Medical Physiology | edition = 2nd | publisher = Saunders | location = Philadelphia | year = 2011 | isbn = 978-1-4377-1753-2 }}

Hydrocortisone is metabolized by 11β-hydroxysteroid dehydrogenases (11β-HSDs) into cortisone, an inactive metabolite. It is additionally 5α-, 5β-, and 3α-reduced into dihydrocortisols, dihydrocortisones, tetrahydrocortisols, and tetrahydrocortisones.{{cite journal | vauthors = Nikolaou N, Hodson L, Tomlinson JW | title = The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies | journal = The Journal of Steroid Biochemistry and Molecular Biology | volume = 207 | issue = | pages = 105808 | date = March 2021 | pmid = 33418075 | doi = 10.1016/j.jsbmb.2021.105808 | s2cid = 230716310 }}

The elimination half-life of hydrocortisone ranges from about 1.2 to 2.0 (SD) hours, with an average of around 1.5{{nbsp}}hours, regardless of oral versus parenteral administration. The duration of action of systemic hydrocortisone has been listed as 8 to 12{{nbsp}}hours.

{{See also|List of corticosteroids|List of corticosteroid esters#Hydrocortisone esters}}

Hydrocortisone, also known as 11β,17α,21-trihydroxypregn-4-ene-3,20-dione, is a naturally occurring pregnane steroid.{{cite book| vauthors = Elks J |title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies |url= https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA316|date=14 November 2014 |publisher=Springer |isbn=978-1-4757-2085-3 |pages=316 |url-status=live |archive-url=https://web.archive.org/web/20170908213347/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA316|archive-date=8 September 2017}}{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA524|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=524–|access-date=19 June 2020|archive-date=10 January 2023|archive-url=https://web.archive.org/web/20230110093813/https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA524|url-status=live}} A variety of hydrocortisone esters exist and have been marketed for medical use.

In March 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Efmody, intended for the treatment of congenital adrenal hyperplasia (CAH) in people aged twelve years and older. The applicant for this medicinal product is Diurnal Europe BV.{{cite web | title=Efmody: Pending EC decision | website=European Medicines Agency (EMA) | date=25 March 2021 | url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/efmody | access-date=27 March 2021 | archive-date=4 May 2021 | archive-url=https://web.archive.org/web/20210504065409/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/efmody | url-status=dead }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Hydrocortisone (Efmody) was approved for medical use in the European Union, in May 2021, for the treatment of congenital adrenal hyperplasia (CAH) in people aged twelve years and older.{{cite web | title=Efmody EPAR | website=European Medicines Agency (EMA) | date=24 March 2021 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/efmody | access-date=14 June 2021 | archive-date=14 June 2021 | archive-url=https://web.archive.org/web/20210614223631/https://www.ema.europa.eu/en/medicines/human/EPAR/efmody | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

In the UK, the Competition and Markets Authority (CMA) concluded an investigation into the supply of hydrocortisone tablets, finding that from October 2008 onwards, drug suppliers Auden McKenzie and Actavis plc had charged "excessive and unfair prices" for 10mg and 20mg tablets and entered into agreements with potential competitors, paying companies who agreed not to enter the hydrocortisone market and enabling Auden McKenzie and Actavis to supply the drugs as "generic" rather than branded products and thereby escape price controls until eventually other companies entered the market. Auden and Actavis overcharged the UK's National Health Service for over ten years. Fines totalling over £255m were levied against the companies involved in this breach of competition law.{{OGL-attribution|Competition and Markets Authority, [https://assets.publishing.service.gov.uk/media/624597bbe90e075f0b5a3da4/Case_50277_Decision.pdf Decision: Hydrocortisone tablets. Excessive and unfair pricing and Anti-competitive agreements], published 31 March 2022, accessed 1 June 2023}}

Hydrocortisone was found to be effective in reducing mortality rate of critically ill COVID-19 patients when compared to other usual care or a placebo.{{cite journal | vauthors = Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LC, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JP, Horby P, Jüni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Møller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC | title = Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis | journal = JAMA | volume = 324 | issue = 13 | pages = 1330–1341 | date = October 2020 | pmid = 32876694 | pmc = 7489434 | doi = 10.1001/jama.2020.17023 | doi-access = free }}

{{Reflist}}

{{Stomatological preparations}}

{{Antidiarrheals, intestinal anti-inflammatory and anti-infective agents}}

{{Vasoprotectives}}

{{Glucocorticoids and antiglucocorticoids}}

{{Corticosteroids}}

{{Otologicals}}

{{Glucocorticoid receptor modulators}}

{{Portal bar | Medicine}}

{{Authority control}}

Category:Alcohols

Category:Antipruritics

Category:CYP3A4 inducers

Category:Glucocorticoids

Category:Ketones

Category:Mineralocorticoids

Category:Orphan drugs

Category:Pregnanes

Category:World Health Organization essential medicines

Category:Wikipedia medicine articles ready to translate